时间/地点： 2018年9月1日 上午 （Sep 1 AM） /  会议室1 （M1）

合作单位：

会议介绍：

Biologic drug products can be composed of sugars, proteins, nucleic acids or combinations thereof – also they may be composed of living entities such as cells and tissues. Frequently, they involve large, complex molecules and are often administered parenterally.

A critical concern in formulation development is the relationship between API concentration and drug product viscosity. Large molecules result in high viscosities, but high viscosity drug products cannot be injected easily. As a result, dilution is performed, which may result in large dosage volumes.

Delivery of large volumes is a challenge. A way to address this is with pre-programmable, easy-to-use, wearable injectors that can deliver larger volumes at a pre-programmed delivery time. West is committed to safe, efficient delivery of drug products to patients.

New research into biologics has helped to develop options for a number of chronic conditions, including diabetes. High-quality containment and delivery systems may help make diabetes treatment better for patients. In addition, for pharmaceutical manufacturers, high-quality products can provide tighter break-loose and extrusion forces and improve manufacturability.

With the right focus on quality systems, patient-centric delivery systems, and unique connectivity to enhance adherence, pharmaceutical manufacturers can provide patients with powerful systems that may help resolve the more challenging problems associated with self-care for chronic conditions.

演讲题目：

演讲嘉宾：

  Bernard W. Lahendro

  Bernard Lahendro, Vice President Relation Partner West/Daikyo.MBA Marketing 

  Saint Joseph’s University.West Pharmaceutical Services for 47 years.Bernard has

  been the primary interface to Daikyo Seiko for 26 years and has been their global spokesperson.  Recently retired from the Daikyo Board of Directors, he still maintains the global spokesperson role in the relationship.

  Glen Zimmermann

  Glen Zimmermann is the Senior Director of Business Development within West’s

  Product Management organization.   Glen has been with West for 22 years with a

  diverse background in finance, corporate development, marketing and business development.  His current responsibilities include developing comprehensive strategies designed to position West’s administration systems device for long-term growth and integrate those offerings into their commercial units.  Over the past eight years Glen has supported West’s growth by expanding their injectable drug delivery platform to include intradermal devices and a new hospital / Point of Care commercial channel.  These and other innovative drug delivery devices will be the subject of his CNPPA presentation.

  Ong Swee Hong

  Ong Swee Hong先生是西氏给药装置产品经理，负责给药装置在亚太市场的营销。他与客

  户密切合作以满足他们各种包装与给药装置的要求。在加入西氏之前，他在多家跨国药企担

  任医疗软件和医药装置的技术支持、项目管理和市场工作。 他拥有新加坡南洋理工大学电气与电子工程学士学位，新加坡管理大学会计学硕士学位。

   付玮

   目前主要负责West产品在中国市场的产品管理和市场开拓， 包括West弹性体密封组件和

   系统，以及新型给药装置的业务开发和推广，研究和把握制药和医药包装行业技术的研究

   热 点，发展趋势和法规需求，从而帮助公司制定和实施中国本地化的产品解决和推广方案。毕业于华中农业大学，拥有微生物和分子生物学硕士学位，在制药和生命科学，以及医药包装有近10年的销售和市场的经验。

您期望通过本次会议学习/了解的内容请在此留言给管理员，谢谢！

请在新打开的页面填写调查问卷或单击此处打开调查问卷。